imatinib has been researched along with Fibrodysplasia Ossificans Progressiva in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohedas, AH | 1 |
| Wang, Y | 1 |
| Sanvitale, CE | 1 |
| Canning, P | 1 |
| Choi, S | 1 |
| Xing, X | 1 |
| Bullock, AN | 1 |
| Cuny, GD | 1 |
| Yu, PB | 1 |
1 other study available for imatinib and Fibrodysplasia Ossificans Progressiva
| Article | Year |
|---|---|
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein K | 2014 |